Association Between NAT2 Polymorphisms and Prostate Cancer
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 2
Abstract
Background NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorigenesis process. Objectives The aim of this study was to assess the possible association between NAT2 polymorphisms (857 G > A, 481 T > C, and 590 G > A) and risk of prostate cancer (PC). Methods Totally, 207 benign prostate hyperplasia (BPH) and 147 PC Iranian patients were evaluated. NAT2 genotypes were detected by restriction fragment length polymorphism (RFLP). Multiple logistic regression models were used to estimate the odds ratios for the association between presence of each genotype and developing PC. Results For NAT2 G857A, the frequency of AA and AG genotypes was lower among PC patients compared to those without it (1.01% vs. 0 and 55.88% vs. 54.55%, respectively; P = 0.7). For NAT2 T481c, the odds ratios for the association of TT and CT genotypes with PC were 0.65 and 0.55, respectively, which were not statistically significant (P = 0.5 and P = 0.09, respectively). For NAT2 G590a, both AA (11.11% vs. 12.87%) and AG (45.83% vs. 52.48%) genotypes were significantly more common among PC patients compared to BPC patients (P = 0.008). However, none of the relevant odds ratios were statistically significant (OR = 2.2, P = 0.2 and OR = 1.72, P = 0.1, respectively). Among PC patients, CT genotype of T481C caused more than 4-fold significant increase in the risk of developing advanced stages of PC. Conclusions Our study represented credible evidence that carrying G857A, G590A and T481C polymorphisms of NAT2 may not affect developing PC, its grading or invasion, but heterozygote genotype of T481C polymorphism (Rapid acetylator) can be associated with more advanced stages of cancer earlier in life. Further longitudinal studies with larger sample sizes are needed to more precisely assess the genetic risk factors of PC.
Authors and Affiliations
Mandana Hasanzad, Seyed Amir Mohsen Ziaei, Vahideh Montazeri, Mahdi Afshari, Seyed Hamid Jamaldini, Mahdieh Imani, Mahshid Sattari, Leila Hashemian, Seyed Rouhollah Kalantar Moaetamed, Mohammad Samzadeh
Keywords
Related Articles
- EP ID EP237298
- DOI 10.5812/ijcp.5716
- Views 81
- Downloads 0
Oncoplastic Breast Surgery; Is It Possible to Perform It in Every Medical Center?
No Abstract
No Detection of Streptococcus gallolyticus and Helicobacter pylori in Colorectal Cancer Tissue Samples in Shiraz, Iran
Background:Worldwide, colorectal cancer is the fourth most common cause of cancer-related deaths. Infectious agents have long been associated with development of gastrointestinal malignancies including colorectal cancer....
Environmental Monitoring of Occupational Exposure to Cyclophosphamide Drug in Two Iranian Hospitals
Background: Most cytotoxic drugs are unable to discriminate normal cells from cancer cells and they interfere with cell division and could lead to harmful effects such as carcinogenicity, genetic mutation, and teratogeni...
Prognostic Factors and Survival of Glioblastoma Multiform (GBM) in Iranian Patients
Background Glioblastoma Multiform has been a common and fatal brain tumor. In this regard, there was ambiguity around patient survival rates in Iran que to data insufficiency. In...
Body Mass Index and Risk of Breast Cancer: A Systematic Review and Meta-Analysis in Iran
Background Various studies in Iran on the role of BMI higher than normal (BMI ≥25) on breast cancer have reported different results. Objective The aim of this systematic review an...